Key facts
- This page summarizes Valetudo Therapeutics LLC's Form 4 filing for Liminatus Pharma, Inc. (LIMN).
- 1 reported transaction and 2 derivative rows are listed below.
- Accepted by SEC: 14 Jul 2026, 17:46.
Valetudo Therapeutics LLC - 02 Jul 2026 Form 4 Insider Report for Liminatus Pharma, Inc. (LIMN)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- LIMN
- Reported as of
- 02 Jul 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 14 Jul 2026, 17:46:07 UTC
- Prior SEC filing
- 06 Jul 2026
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Chris Kim
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Valetudo Therapeutics LLC filed Form 4 for Liminatus Pharma, Inc. (LIMN) on 14 Jul 2026.
Change
- Previous filing in this sequence was filed on 06 Jul 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (2)
CIK 0002067359
Primary reporting owner
Valetudo Therapeutics LLC
- Relationship
- 10%+ Owner
- Address
- 2251 STERN GOODMAN STREET, SUITE E, FULLERTON
- Signature
- By: /s/ Chris Kim
- Signature date
- 14 Jul 2026
CIK 0001972385
Kim Chris
- Relationship
- Chief Executive Officer, Director, 10%+ Owner
- Address
- 2251 STERN GOODMAN STREET, SUITE E, FULLERTON
- Signature
- By: /s/ Chris Kim
- Signature date
- 14 Jul 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LIMN
transaction
Common Stock, par value $0.0001 per share
Other
- Transaction value
- Shares
- +3,448,926
- Change %
- +192%
- Price
- Shares after
- 5,244,351
- Date
- 02 Jul 2026
- Ownership
- Direct
- Footnotes
- F1, F2
LIMN
transaction
Common Stock, par value $0.0001 per share
Other
- Transaction value
- Shares
- +3,448,926
- Change %
- +192%
- Price
- Shares after
- 5,244,351
- Date
- 02 Jul 2026
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LIMN
holding
Derivative
Series A Preferred Stock, par value $0.0001 per share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 48,975
- Date
- 02 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Stock, par value $0.0001 per share
- Underlying amount
- 489,751,074
- Exercise price
- Footnotes
- F1, F2
LIMN
holding
Derivative
Series A Preferred Stock, par value $0.0001 per share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 48,975
- Date
- 02 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Stock, par value $0.0001 per share
- Underlying amount
- 489,751,074
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Consists of 5,244,351 shares of common stock held of record by Valetudo Therapeutics LLC ("Valetudo"). On July 2, 2026, Valetudo received 3,448,926 shares of common stock and 48,975.10742 shares of the registrant's newly designated Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") as consideration paid to former members of InnocsAI LLC ("InnocsAI") in connection with the registrant's acquisition of InnocsAI. Each share of Series A Preferred Stock will be convertible into 10,000 shares of common stock at an issue price of $0.20 per share, which conversion is contingent upon prior stockholder approval of the issuance of the underlying common shares to the extent required under applicable Nasdaq Stock Market LLC listing rules.
Footnote F2
The Series A Preferred Stock has no expiration date. Mr. Chris Kim is the CEO and controlling member of Valetudo and has voting and dispositive power over, and may be deemed to be the beneficial owner of, the shares held by Valetudo. The business address of Valetudo is 2251 Stern Goodman Street, Suite E, Fullerton, California 92833. Mr. Kim disclaims any beneficial ownership of any shares held by Valetudo except to the extent of his ultimate pecuniary interest therein.